RT Journal Article
SR Electronic
T1 Use of autologous platelet derivatives for secondary alveoloplasty in patients with cleft lip and palate: a protocol for a systematic review and meta-analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.28.21259643
DO 10.1101/2021.06.28.21259643
A1 Andrés Campolo
A1 Claudia Heider
A1 Ismael Cañete
A1 María Francisca Verdugo
A1 Rocio Bravo Jeria
A1 Carmen Gloria Morovic
A1 Gabriel Rada
YR 2021
UL http://medrxiv.org/content/early/2021/07/01/2021.06.28.21259643.abstract
AB Objective To assess the effectiveness and safety of autologous platelet derivatives, specifically platelet-rich plasma (PRP) or platelet-rich fibrin (PRF), for secondary alveoloplasty in patients with cleft lip and palate.Eligibility criteria We will include randomized trials evaluating the effect of autologous platelet derivatives on newly bone formed after secondary alveoloplasty in cleft lip and palate patients. Two reviewers will independently screen each study for eligibility, data extraction, and bias assessment using the Cochrane “risk of bias “tool. We will pool the results using meta-analysis and apply the GRADE system to assess the certainty of the evidence for each outcome.Data sources A comprehensive search will include all relevant randomized controlled trials (RCTs), the ongoing investigation reported in specialty congresses and trials regardless of language or publication status (published, unpublished, in press, and progress). We will conduct searches in the following databases: Cochrane Central Register of Controlled Trials (CENTRAL), PUBMED, Embase, and LILACS. We will screen trial registries and other sources in order to identify articles that might have been missed in the electronic searches.Ethics and dissemination As researchers will not access information that could identify an individual participant, obtaining ethical approval was waived.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research received no specific grant from any funding agency in public, commercial or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:As researchers will not access information that could lead to the identification of an individual participant, obtaining ethical approval was waived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis is a systematic review, and all the data included in this study is available from Cochrane Central Register of Controlled Trials (CENTRAL), PUBMED, Embase, LILACS, WHO International Clinical Trials Registry Platform (WHO-ICTRP) (www.who.int/ictrp/), ClinicalTrials.gov (clinicaltrials.gov/) and Google Scholar databases.